

Premier Sponsor



Agenda			
Session Duration	Торіс	Presenter(s)	
60 minutes	What's New in FIP – The European Prospective Understand how the FCoV-23 outbreak in Cyprus appears to have been caused, and how devastating it has been, and what we have learned about it since the outbreak started Understand how Therapeutic Drug Monitoring can be used to optimise the dose of GS-441524 to be given to each individual cat with FIP Know how useful serum AGP concentrations is when deciding when it is safe to stop treatment FIP treatment.	Dr. Danielle Gunn-Moore	
60 minutes	 Diagnostics for FIP Understand the strengths and weaknesses of different tests for the diagnosis of FIP Make recommendations on which test is appropriate for a potential case accounting for contextual factors Understand how to obtain a definitive diagnosis of FIP and when this would be needed. 	Dr. Kerry Rolph	
60 minutes	Treatment of FIP in the Remdesivir Era: How, When and Why to Stop Understand the mechanisms of drugs currently showing success for the treatment of FIP Review current FIP treatment protocols Discuss limitations in the protocols used to dates Strategize how to improve future treatment outcomes.	Dr. Krystle Reagan	
60 minutes	Panel Discussion	Dr. Danielle Gunn-Moore, Dr. Kerry Rolph, Dr. Krystle Reagan Moderator: Kerry Peak	

©ACVIM – all rights reserved



Premier Sponsor



Agenda (cont.)				
Session Duration	Topic	Presenter(s)		
60 minutes	 Lunch and Learn – Presented by Stokes Pharmacy Compounded FIP Medications: Insights, Efficacy and Best Practices Understand the background and recent availability of compounded GS-441524 for FIP in the United States. Gain insights into Bova's role in providing FIP treatment and what distinguishes their approach. Compare and contrast GS-441524 to EIDD-1931 or Molnupiravir and learn when to use each treatment option. Recognize the differences among various compounded FIP medications and their implications for treatment. Address common misconceptions about black market drugs vs. legitimate compounded treatments. Answer frequently asked questions to clarify confusion surrounding FIP treatment options. 	Mickey O'Connor		
60 minutes	 Can Bacteria Cause Cancer? Understand the potential role that some bacterial infections may play in neoplastic processes Select appropriate diagnostics for the identification of bacteria in neoplastic diseases Make recommendations on the treatment of infections in neoplastic diseases. 	Dr Kerry Rolph		
60 minutes	 Known and Emerging Cancer-Causing Viruses in cats. Why Should We Care? Articulate the relevance to feline medicine of identifying oncogenic viruses Understand mechanisms used by retroviruses and papillomaviruses to contribute to feline cancers Identify viruses with oncogenic potential in cats and evaluate current evidence of pathogenic roles. 	Dr. John Munday		

©ACVIM – all rights reserved 2 | P a g e



Premier Sponsor



Agenda (cont.)				
Session Duration	Торіс	Presenter(s)		
60 minutes	 Panel Discussion Evaluate emerging associations between infectious diseases and cancer Discuss the potential for new diagnostics and treatments in some forms of cancer Consider emerging infections and the potential for neoplastic associations. 	Dr. John Munday Dr. Kerry Rolph Moderator: Kerry Rolph		

©ACVIM – all rights reserved 3 | P a g e



Premier Sponsor



©ACVIM – all rights reserved